Get the Stockscreener App
7.63
0.52%
-0.04
After Hours:
7.68
0.05
+0.66%
Candel Therapeutics Inc stock is traded at $7.63, with a volume of 1.83M.
It is down -0.52% in the last 24 hours and up +51.99% over the past month.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
See More
Previous Close:
$7.67
Open:
$7.63
24h Volume:
1.83M
Relative Volume:
1.24
Market Cap:
$559.05M
Revenue:
$31,000
Net Income/Loss:
$-38.18M
P/E Ratio:
-10.88
EPS:
-0.701
Net Cash Flow:
$-38.90M
1W Performance:
+23.46%
1M Performance:
+51.99%
6M Performance:
+54.45%
1Y Performance:
+66.23%
1-Day Range:
$7.50
$7.925
1-Week Range:
$6.11
$7.9884
52-Week Range:
$4.3384
$7.9884
Candel Therapeutics Inc Stock (CADL) Company Profile
Name
Candel Therapeutics Inc
Sector
Industry
Phone
617-916-5445
Address
117 KENDRICK STREET, NEEDHAM
Compare CADL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
7.63 | 561.98M | 31,000 | -38.18M | -38.90M | -0.701 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-20-26 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-28-25 | Initiated | Stephens | Overweight |
| Sep-03-25 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-30-25 | Resumed | H.C. Wainwright | Buy |
| Feb-20-25 | Initiated | Citigroup | Buy |
| Feb-19-25 | Initiated | Canaccord Genuity | Buy |
| Feb-07-25 | Initiated | BofA Securities | Buy |
| Dec-02-22 | Initiated | H.C. Wainwright | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Aug-23-21 | Initiated | Credit Suisse | Outperform |
| Aug-23-21 | Initiated | Jefferies | Buy |
| Aug-23-21 | Initiated | UBS | Buy |
View All
Candel Therapeutics Inc Stock (CADL) Latest News
Candel Therapeutics CEO urges stronger patient role to drive innovation at BioEquityEurope - Traders Union
Candel to discuss phase 3 prostate cancer trial data on May 15 - Investing.com UK
Candel to discuss phase 3 prostate cancer trial data on May 15 By Investing.com - Investing.com Australia
Candel Therapeutics to review Phase 3 prostate cancer data in May 15 call - Proactive financial news
Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting - The Manila Times
Candel lines up May 15 call after prostate cancer trial data at AUA - Stock Titan
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Two new Candel hires get options to buy 29,400 shares at $6.18 - Stock Titan
Candel Therapeutics (NASDAQ: CADL) details 2026 virtual vote on directors and KPMG - Stock Titan
[ARS] Candel Therapeutics, Inc. SEC Filing - Stock Titan
Small cap wrap: C3 Metals, Candel Therapeutics, BioHarvest Sciences… - Proactive financial news
Candel Therapeutics teams up with EVERSANA to prep for prostate cancer drug launch - Yahoo Finance
Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer - The Manila Times
Candel picks EVERSANA over building its own sales force for prostate launch - Stock Titan
BlackRock files Schedule 13G/A reporting 3,079,861 CADL shares (NYSE: CADL) - Stock Titan
How (CADL) Movements Inform Risk Allocation Models - Stock Traders Daily
CADL Forecast, Price Target & Analyst Ratings | CANDEL THERAPEUTICS INC (NASDAQ:CADL) - ChartMill
Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy: Retail Considers It Good Long-Term Buy - MSN
CADL (Candel Therapeutics Inc.) reports wide Q4 2025 EPS miss while notching slight share gains on stable investor sentiment.Hot Momentum Watchlist - Cổng thông tin điện tử tỉnh Tây Ninh
Candel Therapeutics Stock Jumps On Upbeat Q1 Earnings: Retail Gets More Bullish - MSN
Mapping Candel Therapeutics' Sprint To The BLA Finish Line - Bioprocess Online
Candel Therapeutics: 'Cancer Vaccine' Buy Thesis Appears Compelling (NASDAQ:CADL) - Seeking Alpha
CADL Initiated Coverage By Cantor Fitzgerald -- Rating Overweigh - GuruFocus
Candel Therapeutics Stock Soars After Cantor Fitzgerald's Overweight Rating - Benzinga
Insiders Rewarded With US$506k Addition To Investment As Candel Therapeutics Stock Hits US$467m - 富途牛牛
Is Candel (CADL) stock forming a continuation pattern (Leaps) 2026-04-20High Interest Stocks - Cổng thông tin điện tử tỉnh Lào Cai
CADL Stock Posted Its Best Day In Nearly 16 Months On Friday – Why Does Cantor See A Further 370% Upside? - Stocktwits
10 Health Care Stocks Moving In Friday's Intraday Session - Sahm
Targeted oncology therapies expand industry interest for Candel Therapeutics - Traders Union
Trading Systems Reacting to (CADL) Volatility - Stock Traders Daily
Candel Therapeutics, Inc. (CADL) Stock Analysis: Exploring a 266.50% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Candel Therapeutics advances viral immunotherapies in prostate lung and brain cancer programs - Traders Union
Aug Analyst Calls: Should I hold or sell Candel Therapeutics Inc now2026 Recap & AI Enhanced Execution Alerts - baoquankhu1.vn
Form 424B5Prospectus [Rule 424(b)(5)] - ADVFN
Candel Therapeutics, Inc. (NASDAQ:CADL) Given Average Rating of "Hold" by Brokerages - MarketBeat
Candel Therapeutics (NASDAQ:CADL) Downgraded by Zacks Research to Strong Sell - MarketBeat
Candel Therapeutics, Inc. prepares new immunotherapy data release at AUA2026 - Traders Union
Dow Update: Is Candel Therapeutics Inc affected by consumer sentimentMarket Risk Report & Momentum Based Trading Ideas - baoquankhu1.vn
Winners Losers: Can Candel Therapeutics Inc be the next market leaderWeekly Profit Recap & Capital Efficient Trade Techniques - baoquankhu1.vn
Should I Buy Candel (CADL) Stock Now | Price at $5.15, Up 3.00%Hedge Fund Favorites - Cổng thông tin điện tử Tỉnh Sơn La
Candel Therapeutics, Inc. (CADL) Stock Price, News, Quote & History - Yahoo! Finance Canada
CADL Stock Analysis: Candel Therapeutics Inc. Biotech at 5 Dollar Level Post Mild Daily Uptick - Cổng thông tin điện tử tỉnh Tây Ninh
Candel Therapeutics, Inc. (CADL) stock price, news, quote and history - Yahoo Finance UK
Candel Therapeutics Inc. (CADL) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Candel Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Candel Therapeutics (CADL) director granted 4,618 fully vested stock options - Stock Titan
Director at Candel Therapeutics (NASDAQ: CADL) gets 2,795 options - Stock Titan
Candel Therapeutics (CADL) director granted fully vested stock options in lieu of cash fees - Stock Titan
Candel Therapeutics Inc Stock (CADL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):